share_log

HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target

Benzinga ·  06:42

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment